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Abstract: There has been growing interest in robotic exoskeletons over the past two decades, and the use 
of robotic exoskeletons has increased with the development of technology and wider awareness of their 
benefits. Although there have been numerous studies in the area of robotic exoskeletons, the research 
appears to have neglected paediatric population end users. Possible reasons behind this could be the 
continuous growth of children which affects the requirements of the system and also relatively fewer 
number of immobilized subjects in the paediatric population compared to adult population. In this paper, 
firstly a review of state of the art of assistive robotic exoskeletons highlighting the lack of research for 
paediatric population is presented. Secondly, different mobility disorders in children and system 
requirements of an assistive robotic exoskeleton for these disorders are addressed.  
Keywords: Exoskeleton, Robotics, Children, Mobility Disorders, Cerebral Palsy  

1. INTRODUCTION 
Robotic exoskeletons are wearable bionic devices which 
could provide external torque at joints to move that part of 
body. Robotic exoskeletons are classified into three main 
groups in terms of the purpose of use: assistive robotic 
exoskeletons, rehabilitative robotic exoskeletons, and robotic 
exoskeletons for enhancing physical abilities of healthy 
subjects [1]. In addition, based on the body part they are used 
for, robotic exoskeletons are divided into four sub-groups: 
lower extremity exoskeletons, upper extremity exoskeletons, 
specific joint support exoskeletons, and full body 
exoskeletons.  
The aims of this paper are reviewing the state of the art by 
mainly considering assistive lower-body robotic 
exoskeletons, highlighting the lack of research for paediatric 
population, identifying different children mobility disorders, 
and establishing generic and specific system requirements of 
an assistive robotic exoskeleton for these mobility disorders.  
2. STATE OF THE ART 
A considerable body of literature has been published 
regarding robotic exoskeletons for adults. In this section, 
mainly assistive robotic exoskeletons are presented. As 
indicated in the previous section, assistive robotic 
exoskeletons can improve quality of life for paralyzed people 
by assisting them with Activities of Daily Livings (ADLs), 
including walking, sitting down, and standing up. 
2.1 ReWalk 
ReWalk [2, 3] , shown in Fig. 1, is designed by ReWalk 
Robotics company in the US which is a well-known example 
of assistive robotic exoskeleton for adults. ReWalk can be 
used by people with complete Spinal Cord Injury (SCI) for 
ADLs. There are two different products on the market which 
are ReWalk Rehabilitation and ReWalk Personal.  
 
Fig. 1. The ReWalk Personal with an immobilized person 
inside [2]. 
Assistive robotic exoskeletons are very similar to over 
ground rehabilitative walking systems, and they can be used 
for both purposes. Therefore, the design of both ReWalk 
Rehabilitation and ReWalk Personal exoskeletons are the 
same. The only difference between ReWalk Rehabilitation 
and ReWalk Personal is the graphical user interface in the 
ReWalk Rehabilitation exoskeleton which is used by 
therapists to change the level of assistance for each 
individual. In addition, ReWalk Rehabilitation is used as a 
training equipment before starting the use of ReWalk 
Personal in the community.   
ReWalk has 6 Degrees of Freedom (DOFs) and could provide 
sagittal plane movements only by active hip and knee joints 
and passive ankle joint. The exoskeleton is approximately 23 
kg and contains a wearable brace that incorporates DC 
motors at the joints. It has rechargeable batteries which is 
  
     
 
carried by the user in a backpack as well as the computer-
based controller.  
ReWalk has four action modes: sit to stand, stand to sit, up 
steps, and down steps. Tilt sensors are used to determine the 
movements of upper-body, the signal from tilt sensors is 
considered as the intention of the lower-body movement. As 
a safety feature the quick flexion of hip and knee joints are 
prevented which might cause a fall. In addition, in case of a 
power failure, the exoskeleton collapses gently.  
ReWalk was accepted by the U.S. Food and Drug 
Administration (FDA) in 2014 as a personal device and can 
be used by SCI patients. Although it is one of the best 
exoskeleton in the market based on clinical study results [4], 
one important challenge associated with this exoskeleton is 
that there is no self-balance control. Therefore, crutches are 
always needed.  
2.2 Vanderbilt ± Indego  
The Vanderbilt exoskeleton [5-8], shown in Fig. 2 (a), was 
developed by Vanderbilt University for paralyzed people to 
help them to accomplish some daily activities including 
walking, sitting, and climbing stairs. Although the 
exoskeleton was designed by Vanderbilt University, the 
commercialization of it was made by Parker Hannifin 
Corporation according to an exclusive agreement between 
them in October 2012 [9]. After this agreement, the 
Vanderbilt exoskeleton was named as Indego and was 
commercialized in 2015 as two different products: Indego 
Personal and Indego Therapy as depicted in Fig. 2 (b).  
 
Fig. 2. The Vanderbilt exoskeleton, (a) the prototype of 
Vanderbilt exoskeleton by Farris et al. [33], (b) the 
commercialized Indego exoskeleton by Parker Hannifin 
Corporation [9]. 
The Vanderbilt ± Indego exoskeleton has no support between 
the ankle joint and foot. Therefore, an additional support is 
needed as it is included in Fig. 2 (b) for just demonstration 
purpose. Hip and knee joints are actuated in the sagittal plane 
only by two brushless DC motors. The total weight of the 
exoskeleton is 12 kg, which is comparatively lightweight in 
the class of assistive robotic exoskeletons. In addition, the 
average speed of the exoskeleton is 0.8 km/h, which is a 
reasonable speed compared to other available robotic 
exoskeletons in the area.  
The Vanderbilt ± Indego exoskeleton has a unique design. As 
it is clear from Fig. 2, the exoskeleton does not contain a 
backpack for the battery while the battery is placed around 
the waist line. It is a modular exoskeleton and could be 
divided into five parts: a hip segment, two thigh and shank 
segments, which makes the exoskeleton easily wearable. In 
addition, all segments have three different sizes to meet 
GLIIHUHQWSDWLHQWV¶DQWKURSRPHWU\ 
The Vanderbilt ± Indego exoskeleton works in combination 
of Functional Electrical Stimulation (FES) to contract and 
relax the paralyzed muscles of the user. The idea is to 
combine metabolic and robotic power sources while 
obtaining both the physiological advantages of FES and the 
control advantages of the assistive robotic exoskeleton. 
Therefore, the control structure includes two different control 
loops: a motor control loop and a muscle control loop. In 
addition, Indego involves a fall detection system. In case of 
any fall WKH H[RVNHOHWRQ PDNHV TXLFN DGMXVWPHQWV WR XVHU¶V
position to minimize any risk of injury while in case of any 
power failure, knee joints are locked and hips joints are free. 
The Vanderbilt ± Indego exoskeleton has two working 
modes: standby mode, which allows the user to stop between 
modes, and go mode. To begin walking and transit from 
sitting to standing, the user should tilt forward until feeling a 
vibration in the waist. In addition, the level of assistance of 
both the therapeutic and the personal exoskeletons can be 
adjusted to give more independence and control to the users 
where the level of disability is changing from one user to 
another.  
One preliminary assessment of the exoskeleton was 
completed by the development team [5]  with a T10 motor 
and sensory complete injured subject and results show that 
there was a significant enhancement in walking speed while a 
considerable reduction was seen in the metabolic energy 
consumption. After all assessments [5, 7, 8], in March 2016, 
Indego exoskeletons were approved by the U.S. FDA for the 
use with spinal cord injuries either in a clinical environment 
or personal environment.  
In terms of limitations, one major drawback of this 
exoskeleton is the battery life, which is up to 4 hours 
continuous power. A further difficulty arises, however, when 
an attempt is made to support a person weighed more than 91 
kg. In addition, a pair of crutches is still needed to provide 
balance control. Therefore, the use of the Vanderbilt ± Indego 
exoskeleton is limited by three significant factors which are 
power consumption, the weight of the user, and balance 
control.  
2.3 REX 
REX [10, 11] is designed and manufactured by REX Bionics 
Ltd in New Zealand, presented in Fig. 3. The development 
process started in 2003, and the first prototype was 
introduced in 2007. REX can be used by subjects with many 
different mobility disorders, such as different levels of SCI. 
There are currently two different products available: REX P, 
which is intended to be used as a personal device for ADLs, 
and REX Rehab, that is used in clinical environments to 
perform some exercises by patients under the supervision of 
therapists.  
  
     
 
 
Fig. 3. REX with a spinal cord injured subject in it [11]. 
The mechanical structure of REX includes two tethered legs, 
an upper-body support as well as an abdominal support. The 
exoskeleton has 10 DOFs driven by electric motors while the 
supported movements are flexion/extension and 
abduction/adduction at hip joints, flexion/extension at knee 
joints, and at the ankle joints dorsiflexion/plantarflexion and 
eversion/inversion. The length of each part is also quickly 
DQGHDVLO\DGMXVWDEOHIRUGLIIHUHQWVXEMHFWV¶DQWKURSRPHWU\,Q
addition, the exoskeleton comes with two rechargeable and 
exchangeable batteries where each battery last for only one 
hour which makes two hours continuous power. Although the 
battery life is short, the exoskeleton does not require any 
power while standing.  
REX is controlled by a joystick and can be used by many 
different injuries, as stated previously. However, the main 
condition for the user is to be able to use the joystick. In other 
words, REX is only suitable for manual wheelchair users who 
have the control of their upper-body. Besides this minor 
condition, the exoskeleton could only be used by users who 
weigh up to 100 kg, which is an important limitation of the 
exoskeleton. In contrast to these limitations, REX does not 
require any additional support for balance control that makes 
REX the first and only lower extremity exoskeleton which 
does not necessitate any stability support. 
REX is one of the heaviest and bulkiest exoskeletons, 
approximately 48 kg, in the class of assistive robotic 
exoskeletons because of its unique frame design where it is a 
mobility assistance platform rather than a walking device. As 
it is clear from Fig. 3 the user stands on the footplates, and 
the exoskeleton walks on behalf of the user where the user 
makes minimal effort. The user can walk, sit, stand, turn, and 
navigate stairs and slopes with the help of REX. In addition, 
it is the only exoskeleton which can go backward. However, 
the speed of gait and its large mass are major limitations of 
this exoskeleton.   
The evaluation of REX in terms of safety and feasibility is 
still ongoing internationally in the UK, New Zealand, and 
Australia. The initial part of the trial was named as RAPPER 
[12] and involves 56 subjects with SCI. The results of this 
study show that approximately 90% of the participants were 
able to complete the trial and walk with REX without any 
serious problem. The second part of the trial was named as 
RAPPER II, and the interim results are presented by Birch et 
al. [13]. This part involves 20 participants: 15 subjects with 
paraplegia between the levels of T1 to L5 and 5 subjects with 
tetraplegia between the levels of C4 and C8. The results 
indicate that REX is harmless and practicable to assist 
patients either for ADLs or in rehabilitation sessions. It is 
also important to note that REX currently has CE marking 
and available in CE Mark recognized countries, such as the 
UK and Europe. However, it is not available in the US since 
it has not been approved by the U.S. FDA yet.  
2.4 MindWalker 
MindWalker [14, 15] is a research prototype developed by 
University of Twente, Netherlands in 2012. It is a lower 
extremity exoskeleton, as indicated in Fig. 4 and intended to 
be used by subjects with paraplegia who weigh up to 100 kg. 
The aim of the research was to combine the following three 
areas in one exoskeleton: Brain Machine Interface (BCI) 
technology, Virtual Reality (VR), and exoskeleton 
mechatronics and control.  
 
Fig. 4. MindWalker exoskeleton [16]. 
MindWalker has 6 activate DOFs, powered by series elastic 
actuators, and 4 passive DOFs assisted by springs, 10 DOFs 
in total. Actuated movements are abduction/adduction and 
flexion/extension at hip joints, flexion/extension at knee 
joints while passive movements are 
plantarflexion/dorsiflexion at ankle joints and 
internal/external rotations at hip joints. The weight of the 
exoskeleton is 28 kg excluding batteries, and its maximum 
speed is 0.8 m/s. The displacement of centre of mass 
stimulates the finite state-based controller to initiate 
movements. In addition, a pushbutton is used to start and stop 
the walking of the exoskeleton. 
The preliminary evaluation results show that healthy subjects 
are able to walk without any additional balance support 
device while paraplegic subjects are not able to walk without 
crutches [16], where the main aim of the project was to 
provide walking without crutches.  Therefore, the 
exoskeleton is still under development and evaluation 
process.  
2.5 EksoGT 
EksoGT [17] is designed by the Ekso Bionics Company in 
the US. EksoGT was initially intended for military use. 
However, it was later converted for use as a rehabilitative 
exoskeleton, but it is an over ground walking system as it is 
clear from Fig. 5. Additionally, it could be used as an 
assistive robotic exoskeleton. The exoskeleton consists of 
  
     
 
two aluminium legs, a battery, and a backrest to attach 
different kind of loads.  
 
Fig. 5. EksoGT exoskeleton with a patient inside [17]. 
EksoGT was designed to be adaptable to a wide range of 
patients, including paralyzed and post stroke patients. 
Therefore, the degree of assistance provided by the 
H[RVNHOHWRQ FDQ EH DGMXVWHG WR PHHW HDFK SDWLHQW¶V XQLTXH
needs. It weighs approximately 20 kg and can achieve a 
maximum speed of 0.8 m/s. The exoskeleton has 6 DOFs, but 
only provides movements in the sagittal plane. Its hip and 
knee joints are actuated, while the ankle joint is sprung and 
passive. EksoGT has four use modes: therapist actuates steps 
by using a button, user actuates steps by using a button, user 
achieves the next step by moving the hips laterally, and steps 
that are done by the intention of the user. In addition, as a 
unique feature, the actuators could be controlled individually.  
The length of each part is adjustable to adapt patient whom 
height is ranging from 158 to 195 cm. The use of EksoGT 
has the advantages of high manoeuvrability, strength of the 
structure, and its ergonomics while one of the main limitation 
is that it is only suitable for patients weighing maximum 100 
kg. Furthermore, the battery life of the EksoGT is 6 hours for 
a single charge, and in the event of power failure, knees are 
locked and hips are free to protect the patient from fall.  
In 2016, EksoGT was approved by the U.S. FDA for treating 
SCI levels to C7 and stroke patient, which makes it first 
approved robotic exoskeleton for the use of stroke patients. 
EksoGT is verified by the worldwide clinical studies which 
confirm that EksoGT has significant impact on the regaining 
the abilities of correct gait pattern [18] while there is still no 
major improvement in the step and stride length and cadence. 
It is still under development, with the aims of reducing its 
weight and improving the adaptability to different patients.  
2.6 HAL 
The Hybrid Assistive Limb (HAL) [19] is one of the most 
enthusiastic robotic exoskeleton covered in this paper. It is 
developed by the University of Tsukuba in Tsukuba, Japan, 
and cybernics technology is used in this exoskeleton, which 
makes HAL a unique design. Cybernics technology is a 
multidisciplinary area which combines neuroscience, 
mechatronics, and information technologies. In other words, 
brain signals are used in the control loop to determine the 
intention to move any limb.  
There are currently four different versions of HAL 
exoskeleton: a full-body version, a lower-body version, a 
single-leg version, and a single-joint version. HAL is of 
interest because it is the only full-body robotic exoskeleton 
that is currently on the market. In addition, HAL can be used 
for different purposes such as an assistive product or 
therapeutic product or a human performance enhancement 
product.  
The assistive device, HAL-1 [19], is the first developed 
prototype of HAL in 1999, which is only a lower-body 
exoskeleton, and shown in Fig. 6 (a). The focus was on 
assisting immobilized subjects to perform ADLs. The 
mechanical structure consists of 4 DOFs, and 
flexion/extension movements at both hip and knee joints are 
actuated by DC servo motors. As a second version of this 
exoskeleton, HAL-3 [20] was designed between 1999 and 
2003, which is depicted in Fig. 6 (b). The structure is the 
same as the previous version, HAL-1, and has 4 DOFs. This 
lower-body type exoskeleton weighs 15 kg while the frame is 
made of aluminium alloy and steel. Compared to HAL-1, 
HAL-3 is more suitable for daily use [19].  
 
Fig. 6. HAL robotic exoskeleton, (a) the first prototype HAL-
1, and (b) the second product HAL-3 [19]. 
The assistive HAL has been improved since then, and it is 
currently in a more modern structure. In Fig. 7, both the two-
leg version (a) and the single-leg version (b) of modern HAL 
are shown. It is currently commercialized with the name of 
µ+$/ IRU /LYLQJ 6XSSRUW¶ [21]. The actuated joints are the 
same as with the previous version where there are 2 active 
DOFs at each leg.  
 
Fig. 7. Modern HAL for Living Support, (a) the two-leg 
version, (b) the single-leg version [21]. 
There are currently 3 different sizes available: Small (S) size 
is for users between 145 cm and 165 cm height while 
Medium (M) size is for users between 150 cm to 170 cm 
height, and Large (L) size is for the users between 165 cm to 
185 cm. In addition, both the upper-leg and the lower-leg 
  
     
 
lengths are adjustable with a number of notches where there 
is 1.5 cm gap between each of them. The double-leg version 
is approximately 12 kg, excluding the lithium polymer 
battery, while the single-leg version is 7 kg. The battery can 
provide between 60 minutes to 90 minutes continuous power. 
Besides having relatively short battery life, a further key 
limitations of this device is that the use of it is limited by the 
weight of the user, maximum 80 kg, which is quite low when 
considering the increasing weight of population across the 
world [22].  
In terms of therapeutic device, HAL-Medical [23] is 
designed. The mechanical structure is exactly the same as the 
assistive device. The control algorithm for this device is 
designed to teach the brain how to walk. HAL-Medical is 
currently on the market in Japan and Europe. In addition, it is 
the only therapeutic device that has been approved by CE 
Marking (CE 0197). The feasibility of HAL-Medical is 
reported by Grasmucke et al. [24] after 4 years of using the 
device with 20 acute and 40 chronic SCI subjects. This study 
also indicates the safeness of HAL-Medical for the use with 
acute and chronic SCI patients without any problem. The 
feasibility and suitability of HAL-Medical is also verified by 
Cruciger et al. [25]  and Fujii et al. [26].  
2.7 Exoskeletons specifically for children 
The research on robotic exoskeletons to date has tended to 
focus on adults rather than children. Therefore, the existing 
literature on neither assistive robotic exoskeleton nor 
therapeutic robotic exoskeleton for children are insufficient. 
One possible reason of this could be the continuous growth of 
children which continuously affects the requirements of the 
system. 
2.7.1 ATLAS 
A preliminary concept of  lower limb robotic exoskeleton for 
children is ATLAS [27]. ATLAS was specially designed to 
assist sagittal plane movements of a girl with quadriplegia 
who could not move any of her limbs. This was a system 
with 6 DOFs while only the hip and knee joints were 
powered. It was designed to be portable, lightweight (6.5 kg), 
comfortable and safe for providing gait assistance. This 
proposed approach was experimentally validated. However, 
the challenges that are associated with this design are power 
supply, which needs to be portable and have long life, being 
lightweight, and powerful actuator. 
A second part of ATLAS project has been done which is 
ATLAS 2020 [28, 29] and was not designed for only a 
specific user. It is an easily adaptable exoskeleton for 
children between 3 to 14 ages to provide them 3D walking 
with 10 DOFs. Although it is not displayed in Fig. 8, there is 
an auxiliary frame attached to the exoskeleton for balance 
control. In addition, the exoskeleton is 14 kg which is a 
further significant limitation of ATLAS 2020.  
 
Fig. 8. ATLAS 2020, worn by a disable user [28]. 
As mentioned above, ATLAS 2020 does not have self-
balance control. Therefore, a further version, ATLAS 2030 
[30], was develop with self-balance control by removing the 
frame. It has the same specifications with ATLAS 2020 such 
as providing 3D walking with 10 DOFs and targeting 
children from 3 to 14 years old. Nevertheless, ATLAS 2030 
is still 14 kg which is an enormous weight for a 3 years old 
child.  
2.7.2. WAKE-up 
Wearable Ankle Knee Exoskeleton (WAKE-up) [31, 32] is a 
further multi-joint lower limb exoskeleton designed for 
rehabilitation of children with neuromuscular diseases. 
WAKE-up is not a full lower-body exoskeleton, as indicated 
in Fig. 9 (Appendix A). It is a modular exoskeleton involving 
two separate joint modules: a knee joint module and an ankle 
joint module. In Fig. 9 the detailed illustration of joint 
modules are indicated. Each module has 1 DOF that makes 
the two-leg version of WAKE-up 4 DOFs. The weight of 
each module is 2.5 kg, and Rotary Series Elastic Actuators 
(RSEAs) is used to enhance the safety of users.  
 
Fig. 9. The details of the WAKE-up system with joint 
modules and shoe pad [32]. 
The WAKE-up could assist sagittal plane movements only, 
and the target age group is from 5 years old to 13 years old 
children with neuromuscular disease such as Cerebral Palsy 
(CP). The exoskeleton was tested with four healthy children 
and three children with CP by the same research team. The 
results show that the exoskeleton has positive impact on 
physical gait patterns. However, as it was mentioned by the 
authors as well, the robustness of the system is needed to be 
improved. 
2.7.3 An Active Exoskeleton Designed by Lerner et al. [33] 
  
     
 
A recent study by Lerner et al. [33] describes the design of an 
active single-joint robotic exoskeleton for children with CP. 
The aim of the presented system is to assist knee extension to 
address crouch gait in children. The exoskeleton was 
designed as a knee-ankle-foot orthosis system. Consequently, 
this design cannot be classified as a full lower-body 
exoskeleton.   
The mechanical structure of the exoskeleton, as presented by 
Lerner et al. [33], is based on a modular approach, and its 
total weight is 3.2 kg. The exoskeleton consists of 1 DOF for 
per leg at the knee joint, and brushless DC motors are used as 
actuators to provide adequate assistance for the knee 
extension.  
The clinical trial [33] proved that the exoskeleton reduces the 
level of crouch in children with CP. However, some 
limitations were associated with this exoskeleton. One source 
of weakness identified in the study was the lack of 
participants in the experimental process which involved just 
one applicant. Secondly, a separate 1.96 kg control box was 
not carried by the participant during the experiment. Finally, 
during the clinical trial, the exoskeleton was powered by a 
tethered supply although the battery should be carried by the 
user in practice. If both the control box and the battery are 
carried by the user, the total weight of the exoskeleton would 
increase; thus, this affects the inertia of the movements. In 
addition, weight is one of the major challenges associated 
with all robotic exoskeletons.   
2.7.4 CPWalker 
In Fig. 10 the concept of CPWalker [34] is shown which is a 
treadmill-based rehabilitative robotic exoskeleton designed to 
rehabilitate children with CP. CPWalker includes two main 
components: smart walker part and exoskeleton part. The 
smart walker part could provide balance control with 
dynamic weight support while the exoskeleton part helps 
patients to move their limbs. All three joints, hip, knee, and 
ankle joints, are actuated with brushless DC motors. The 
system is still under development to be adaptable with 
different disorders from CP. 
 
Fig. 10. The concept of CPWalker exoskeleton system [34]. 
2.8 Summary 
The reviewed literature revealed remarkable improvements in 
general in robotic exoskeletons. Although, the majority of the 
available research focused on developing systems for adults, 
some preliminary models of exoskeletons have been designed 
for children with their special needs, in the past few years.  
In Appendix A, a summary of specifications of reviewed 
exoskeletons is provided. As it is clear, most of them require 
to use of crutches for balance control. However, there is no 
way to use crutches or any other additional device to assist 
fully paralyzed patients. Therefore, providing self-balance 
control is vital in the matter of addressing a larger community 
of immobilized population. A further important point is that 
increasing the number DOF is needed in terms of providing 
more natural-like human movements. However, increasing 
the DOF can also lead to high energy consumption which is a 
further key issue for the robotic exoskeletons.  
One of the significant limitation that associated with all types 
of robotic exoskeletons is the safeness of the system [35-40]. 
Therefore, the U.S. FDA announced that all active robotic 
exoskeletons are classified as Class II medical devices which 
contain moderate to high risk factor because of risk of fall, 
sudden blood pressure changes, premature battery failures, 
skin abrasions, and electric shocks [38]. Besides the safety 
issues, there are still many other challenges associated with 
all types of exoskeleton, such as the mechanical design of the 
exoskeleton, actuators, heavy equipment, noise in use, energy 
efficiency issues, the human ± exoskeleton interface, and 
cost. 
Any further development of robotic exoskeleton in the future 
seems to be in two new directions: soft robotics and modular 
robotics [38]. Soft robotics is an innovative way of designing 
lightweight robotic exoskeletons by reducing the total weight. 
In addition, soft robotic exoskeletons could be used for 
patients who have difficulties to fit into the current rigid 
exoskeletons because of their unusual body posture. On the 
other hand, modular robotic exoskeletons could be 
specifically used for the support of single joints where 
needed. In addition, it could make the exoskeleton easily 
wearable by dividing the exoskeleton into modular parts.  
3. DISORDERS AFFECTING CHILDREN 
Movement disorders could be defined as neurologic 
syndromes, which can lead to either excess of movement or 
lack of movement [41]. Movement disorders are broadly 
classified into two main groups: hypokinetic movement 
disorder, which is lack of movement, and hyperkinetic 
movement disorder, which is excess of movement [42]. 
Hypokinetic movement disorders include Parkinsonism, 
apraxia, bradykinesia, and hesitant gait while hyperkinetic 
movement disorders involve tremor, dystonia, chorea, and 
tics.  
In the paediatric population hyperkinetic movement disorders 
are more common than hypokinetic movement disorders [42], 
which mainly result in immobilization. This might be one of 
the reason behind why there is lack of research in robotic 
exoskeletons for children and why children are neglected in 
this area. Although mobility disorders are relatively rare in 
paediatric population, there is a considerable number of 
children have difficulties with mobility. In this section, some 
  
     
 
disease and disorders are presented which could lead to child 
immobilization.  
3.1 Cerebral Palsy 
Cerebral Palsy (CP) is one of the most common and severe 
physical disorder with the prevalence of 2.5 per 1000 
children in developed countries [43], and its prevalence rate 
has not changed for last 60 years [44]. The term of CP is used 
to describe a wide group of permanent disorders including 
developmental disorders and movement disorders. CP is 
basically the result of abnormalities in the brain. The signs 
and symptoms can be seen from the beginning of pregnancy 
or any time in the early childhood.  
Children with CP usually have motor disorder, such as 
difficulties in performing basic ADLs,  rather than learning 
disorders, but sometimes some learning difficulties may be 
seen depending on the severity of CP level [43]. Currently, 
there is no cure for CP. However, some assistive devices, 
such as robotic exoskeletons or standing frames could be 
used to improve the quality of life of individuals with CP 
[44].  
The classification of CP can be made in three different ways: 
based on motor-type, topography, or gross motor function of 
the disorder [45]. Motor-type and topography based 
classifications are traditional classification systems, and the 
GHILQLWLRQRIDQLQGLYLGXDO¶VGLVDELOLW\FRXOGEHLQERWKRIWKLV
classes because of their very generalized borders [43]. 
Therefore, as a reliable classification method gross motor 
function classification system is preferred by experts.  
Motor-type classification system consists of four sub-groups: 
spasticity, dyskinesia, ataxia, and hypotonia [43]. Spasticity 
is the most common type of CP, and it is the term used to 
describe the circumstances when muscles are overactive. This 
could result in gait disturbances, pain, and muscle weakness. 
Dyskinesia involves involuntary and uncontrolled muscle 
movements while ataxia leads to balance and coordination 
problems and locomotion difficulties. Finally, hypotonia 
occurs when there is decreased muscle tone, and this is the 
least common type of CP. In addition, it is also reported that 
30% of individuals with CP are classified into more than one 
group [46]. This shows that motor-type classification system 
is a poor system in terms of reliability.  
Topography based classification system has three categories: 
hemiplegia, diplegia, and quadriplegia (tetraplegia) [43]. 
Hemiplegia is the paralysis of one side of the body, and 
upper-body extremities are more affected than lower-body 
extremities. In diplegia, both lower-body extremities are 
more severely affected than upper-body extremities. Finally, 
quadriplegia (tetraplegia) is the case when all limbs are 
paralysis. As it is very clear, this classification system is also 
very generalized and could not meet with needs.  
Finally, based on gross motor function classification system 
CP is divided into five different level in terms of the severity 
of disorder [43]. Individuals in Level I can sit and walk 
without any assistance while subjects in Level II walk with 
assistive devices and sit with some minor balance problems. 
Level III subjects can only walk short distances indoors with 
assistance. In contrast, Level IV subjects can only creep 
instead of walking for short distances and can sit when they 
are placed. Finally, Level V subjects cannot even sit or walk 
independently. 
3.2 Spinal Muscular Atrophy 
Spinal Muscular Atrophy (SMA) is a relatively rare but a 
progressive genetic disease with the prevalence of 
approximately 1 in 6000 people [47]. In contrast, the carrier 
frequency of SMA is high which is 1 in 50 people [48]. It is a 
severe genetic disease mainly affecting children and leading 
to child mortality and immobilization across the world [49]. 
Basically, it is the result of a mutation occurs in survival 
motor neuron 1 (SMN1) gene, which is the gene responsible 
for producing protein for motor neurons [50]. When there is a 
disruption in production of protein in SMN1 gene, survival 
motor neuron 2 (SMN2) gene is activated to compensate the 
lack of protein in motor neurons [51]. However, SMN2 gene 
could only provide a small amount of protein, which is not 
able to completely compensate the need. Therefore, as a 
result of protein shortage, muscle weakness occurs, mainly in 
muscles used for ADLs, and severity of the muscle weakness 
addresses the type of SMA [52].  
SMA can be classified into four main types based on the 
severity of the disease: Type I, Type II, Type III, and Type 
IV [48, 53]. According to Ogino et al. [54], 58% of all 
subjects with SMA diagnosed as Type I SMA while 29% is 
Type II SMA, and 13% is Type III SMA. Although SMA is 
principally categorized into four main groups, each subject 
with SMA has a unique progression, and it is difficult to 
classify. Distinguishing symptoms are progressive loss of 
independency and immobilization.  
Firstly, Type I SMA, which is also named as Werdnig-
Hoffman disease [53], is the most severe form of SMA. The 
symptoms of Type I SMA could be seen at birth or within a 
few months after birth. Subjects with Type I SMA can never 
be able to sit unassisted or support their head. In addition, 
breathing problems could also be seen. The life expectancy 
for Type I SMA patients is less than 2 years. Secondly, Type 
II SMA is developed between 6 and 12 months after birth, 
and subjects could live into adulthood [48]. The maximum 
independency of subjects is being able to sit without support. 
However, these subjects can never stand or walk 
independently.  
Type III SMA is a milder version of the disease, which is 
also named as Kugelberg-Welander disease [53]. This type of 
SMA could be developed from early childhood to 
adolescence, and subjects could survive into adulthood. 
Subjects with Type III SMA could stand and walk 
independently in the early period of diagnosis, which is the 
difference between Type II SMA and Type III SMA. 
However, approximately half of all individuals with Type III 
SMA lose their ability to walk by age 14 [48] because as 
mentioned earlier, SMA is a progressive disease. Finally, 
Type IV SMA is the mildest type of SMA and can occur after 
  
     
 
age 30 [53]. Subjects could experience mild muscle weakness 
mostly in their upper arms and legs. Individuals with Type IV 
SMA could stand and walk independently. However, they 
might lose this ability later.  
In terms of treatment of SMA, the Spinraza drug is the only 
available drug for the treatment [55]. The U.S. FDA 
approved Spinraza  at the end of 2016 [56]. The effectiveness 
of this drug is under the evaluation process, and preliminary 
tests on mice are promising [52, 57-59]. However, the result 
of using this drug is just minimizing the effects of SMA 
rather than providing complete cure for it.  
3.3 Spinal Cord Injury 
Spinal Cord Injury (SCI) is the result of any damage to the 
spinal cord which blocks or disrupt the communication 
between brain and body [60]. SCI affects sensory and motor 
functions, and it is classified in two different ways: 
paraplegia/tetraplegia or complete/incomplete [61]. Firstly, 
paraplegia is the paralysis of lower-body while tetraplegia is 
the complete or partial loss of upper and lower-body 
functions. Secondly, complete SCI means that all functions 
below the injured nerves are stopped which leads to paralysis 
of the body below that point while incomplete SCI refers to 
that some functions and sensations below the injured nerves 
are still functioning.  
The causes of SCI could be addressed in two groups: 
traumatic injuries and non-traumatic injuries [62]. Traumatic 
causes are motor vehicle accidents, falls, and sportive 
activities while non-traumatic causes are based on illness, 
such as cancer, osteoporosis, inflammation of spinal cord, 
arthritis, and sclerosis. Universally, motor vehicle accidents 
and falls are the most common causes of SCI between these 
causes [60, 63, 64]. For instance, the rate of motor vehicle 
related SCI is approximately 55% of all paediatric SCI in the 
US [63].    
Before the injury levels are described, it is important to 
mention the basic anatomy of spinal cord. Spinal cord is 
covered with ring shaped bones named vertebrae, and 
vertebrae are divided into five main regions: cervical (C1 ± 
C8), thoracic (T1 ± T12), lumbar (L1 ± L5), sacral (S1 ± S5), 
and coccyx nerves [62]. Cervical nerves are located on neck 
area while thoracic, lumbar, sacral, and coccyx nerves are 
respectively located on chest, low back, pelvis, and tail bone 
areas. The severity of SCI depends on the place of the 
damage occurred on vertebrae regions, and it decreases from 
cervical nerves to coccyx nerves.  
The most severe form of SCI is the result of any damage that 
occurred on the high-cervical nerves (C1 ± C4) [62]. Subjects 
within this level of injury become fully paralyzed and lose 
the control of upper and lower extremities. In addition, they 
might have difficulties in breathing and control of bowel 
movements. In contrast, any damage to low-cervical nerves 
(C5 ± C8) can lead to the paralysis mainly in lower 
extremities, and individuals might be able to breath and 
speak. Secondly, thoracic nerves damages (T1 ± T12) mainly 
affect chest, mid-back, and abdominal muscles. Patients with 
this level of injury might stand in a standing frame while they 
still use their upper-body extremities as usual. Finally, 
lumbar nerves damages (L1 ± L5) can cause functional 
impairment in the hip and legs while sacral nerves damages 
(S1 ± S5) could lead to temporary loss of some lower-body 
functions.  
The certain number of people suffered from SCI is not 
known. However, according to World Health Organization 
(WHO) [65], the annual incidence rate of SCI is between 250 
000 to 500 000, and the paediatric SCI population constitutes 
6 ± 10% of it [64, 66]. The injury level in the paediatric 
population is usually high-cervical nerves damages, which is 
the most severe form of SCI. Paediatric SCI is different from 
adult SCI in terms of a higher potential recovery chance and 
the mechanism of injury while each subject has a unique 
form of disability [66]. Therefore, providing rehabilitative or 
assistive robotic exoskeletons for these subject could increase 
their chance to recover.  
3.4 Stroke 
A further rare, but, serious disease that affects children and 
leads to immobilization and mortality is paediatric stroke. 
Basically, stroke is the result of blockage or breakage of 
blood vessel in the brain which lead to permanent or 
temporary brain damage [67, 68]. There are two main sub-
groups of stroke: ischemic stroke, which occurs when there is 
a blockage of blood vessels, and haemorrhagic stroke, which 
occurs when there is a breakage of blood vessel [69]. 
Ischemic stroke is also divided into two sub-groups: arterial 
ischemic stroke and cerebral venous sinus thrombosis. 
Arterial ischemic stroke occurs when the blockage occurs in 
an artery vessel while cerebral venous sinus thrombosis 
occurs as a result of blockage in a vein vessel [67].  
In the paediatric population, approximately half of all stroke 
cases  is arterial ischemic stroke [70], that makes it the most 
common type of paediatric stroke. The incidence of arterial 
ischemic stroke is between 2 to 3 cases per 100,000 cases 
each year for subjects younger than 5 years of age while it is 
between 8 to 13 cases per 100,000 cases each year for 
subjects from 5 to 14 years of age [71].  
The causes and risk factors of paediatric stroke might be 
cardiac diseases, infections, hematologic disease, trauma, 
drugs, and syndromic and metabolic disorders [69]. In terms 
of paediatric stroke, cardiac diseases are the most common 
source of stroke with the rate of 33% of all arterial ischemic 
stroke [72]. Sickle sick disease is a further common source of 
paediatric stroke with the rate of 285 cases per 100,000 cases 
[73].   
The symptoms of stroke in young children are different from 
adults which might lead to misdiagnosis [74]. For instance, 
the symptoms of stroke in a toddler could be continuous 
crying, feeding difficulties, and sleepiness while speaking 
difficulties, vision abnormalities, dizziness, balance and 
walking problems, and weakness of one side of body could 
be seen as the symptoms of stroke in adults. The symptoms 
  
     
 
of stroke are more adult-OLNH DV WKH VXEMHFW¶V DJH LQFUHDVHV
[69].  
After sustaining stroke, some temporary and some permanent 
impairments could be seen including speech and language 
disorders, epilepsy, cognitive and behavioural impairments, 
and psychologic complications and more importantly 
hemiparesis and movement disorders, which cause 
immobilization of subject [69]. Hemiparesis, which is 
permanent weakness of one side of body, is the most 
common outcome of stroke [73-75]. 
3.5 Spina Bifida 
Spina bifida is a type of neural tube defect [76]. It occurs 
when the neural tube cannot complete its development during 
early weeks of pregnancy and still open after birth. Babies 
with spina bifida often have a sac on their back to cover the 
gap, which is a skin with a fluid inside. Spina bifida is the 
most common type of neural tube defect with a rate of 1 in 
2500 new-borns worldwide [76]. The cause of spina bifida is 
still unknown. However, lack of folic acid during the 
pregnancy seems a significant source of spina bifida [77].  
There are mainly three types of spina bifida: 
myelomeningocele, meningocele, and spina bifida occulta 
[77]. Firstly, myelomeningocele is the most common form of 
spina ELILGD LQ ZKLFK WKH VXEMHFW¶V VSLQDO FDQDO LV VWLOO RSHQ
along many vertebrae. In this form of spina bifida, spinal 
cord and protective membranes can be pushed out from the 
sac on the back of subject. Secondly, meningocele is also a 
severe form of spina bifida. The difference between 
myelomeningocele and meningocele is that in meningocele 
type of spina bifida only spinal cord is pushed out, and with a 
surgery this could be solved with a minimum damage to the 
nerves. Finally, spina bifida occulta is the mildest form of 
spina bifida. However, it is the most common form of it. In 
this form of spina bifida, only a few vertebrae are not 
developed properly, and a small gap occurs in the spine. This 
type of spina bifida does not lead to any problem, and many 
subjects with it live without knowing it.  
In terms of treatment, although surgery could be a solution to 
close the gap in the spine and give subject chance to live into 
adulthood, the damage made in the nervous system cannot be 
restored [77]. Therefore, some permanent problems occur, 
including weakness or paralysis of legs and loss of skin 
sensation in the lower-body. In this case, rehabilitation 
therapies and assistive robotic exoskeletons are crucial 
elements in terms of improving the independence of subject. 
4. GENERIC AND SPECIFIC SYSTEM REQUIREMENTS OF 
AN ASSISTIVE ROBOTIC EXOSKELETON FOR CHILDREN  
In this section, some generic and some specific system 
requirements of an assistive robotic exoskeleton for children 
who have any of the disabilities described above are 
presented. First of all, it is important to know the maximum 
level of independency of individual at each level of 
disabilities although it is difficult to generalize disabilities 
where each subject has her/his own unique disability. In 
Appendix B the maximum level of independency for 
different levels of each disorder is addressed, which have 
already been mentioned in the previous section. By 
considering this table Level I CP, Type IV SMA, and spina 
bifida occulta are out of scope because Level I CP and spina 
bifida occulta subjects are still able to stand and walk without 
any assistance, and Type IV SMA occurs after 30 years of 
age.  
In terms of generic design aspects for an assistive robotic 
exoskeleton, it is crucial to primarily consider the comfort 
and safety of users for all different level of disabilities. 
Secondly, the mechanical structure of the exoskeleton should 
be light weight because the mass of the exoskeleton affects 
WKHLQHUWLDRIXVHU¶VMRLQWV[37]. Furthermore, the exoskeleton 
should be able to provide full range of motion as a healthy 
subject could have, which is also related to the comfort of the 
user.  
In terms of specific design aspects, one of the most important 
issues is the balance control of the exoskeleton by 
considering the abilities of subjects from different type and 
level of disorder. The balance control of an assistive robotic 
exoskeleton could be done in two different ways either with 
the use of crutches/standing frames or providing self-balance 
control. Use of additional assistive tools for balance control 
requires full upper-body functioning of the user. Therefore, it 
is necessary to provide self-balance control for subjects with 
upper extremity disorders, such as subjects with high-cervical 
nerves damages.  Moreover, a modular design approach 
could be beneficial for subjects who have partial body 
impairments, such as post-stroke patients. Modular design 
could also affect the comfort of the use by decreasing the 
time spent on wearing the exoskeleton.  
5. CONCLUSION 
Previous design and developments in robotic exoskeletons 
are presented in this paper, and there is no doubt that the 
research which has been carried out specifically for paediatric 
population is insufficient. As stated previously, there might 
be two main reasons behind this circumstance: continuous 
growth of children and comparatively fewer number of 
children with ambulation disorders. However, although it is 
comparatively lower, the number of children with mobility 
disorders is certainly unneglectable. Therefore, different 
mobility disorders are addressed which mainly affects 
children, such as CP, SMA, and spina bifida. Then, generic 
and specific system requirements of an assistive robotic 
exoskeleton are established. One key issue with establishing 
system requirements is that each individual has a unique 
disability, and it is difficult to generalize the requirements. 
However, at very basic level, generic system requirements 
could be listed as comfort and safety of users, range of 
motion, and system weight while balance control of the 
system should be considered as a specific requirement for 
each individual.  
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Appendix A. SPECIFICATIONS OF ALL EXOSKELETONS COVERED IN THE PAPER 
Exoskeleton Total DOF Weight Approval Actuator Type Actuated Joints 
Self-
balance 
control 
Stage 
ReWalk [3] 6 DOFs 23 kg FDA DC motor Hip and knee No Commercial 
Indego [9] 6 DOFs 12 kg FDA DC motor Hip and knee No  Commercial 
REX [11] 10 DOFs 48 kg 
CE 
Marking Electric motor 
Hip, knee and 
ankle Yes Commercial  
MindWalker 
[14] 
10 
DOFs 
28 kg 
(excluding 
batteries) 
Not 
approved SEA Hip and knee No Research/Prototype 
HAL-
Medical [23] 6 DOFs 
12 kg 
(excluding 
batteries) 
CE 
Marking  
DC servo 
motor Hip and knee Yes Commercial  
EksoGT [17] 6 DOFs 20 kg FDA Electric motor Hip and knee No  Commercial 
ATLAS 
2020/2030 
[28, 30] 
10 
DOFs 14 kg 
Not 
approved DC motor 
Hip, knee and 
ankle Yes 
Research/Prototype 
(under clinical 
evaluation process)  
WAKE-up 
[32] 4 DOFs 10 kg 
Not 
approved RSEA Ankle and knee No Research/Prototype 
The 
Exoskeleton 
by Lerner et 
al. [33] 
2 DOFs 3.2 kg Not 
approved DC motor Knee No Research/Prototype 
CPWalker 
[34] 6 DOFs 
Not 
mentioned 
Not 
approved DC motor 
Hip, knee and 
ankle No Research/Prototype 
 
  
     
 
Appendix B. MAXIMUM ACHIEVED INDEPENDENCY OF INDIVIDUALS FOR EACH LEVEL OF DISORDER 
Disorder/Disease Type/Level Maximum achieved independency  
CP 
Level I Sit and walk without any assistance 
Level II Sit with minor balance issues, walk with assistive devices 
Level III Walk only for short distances 
Level IV Creep only for short distances 
Level V Cannot sit/walk independently  
SMA 
Type I Never sit unassisted or support their head 
Type II Sit, but never stand or walk independently 
Type III Can stand and walk in the early periods (but then cannot) 
Type IV Stand and walk (might lose these abilities)  
SCI 
High-cervical nerves damage 
(C1 ± C4) Fully paralyzed, difficulties in breathing 
Low-cervical nerves damage 
(C5 ± C8) Paralysis in lower extremities, cannot walk 
Thoracic nerves damage (T1 ± 
T12) Normal use of upper-body, might stand on a standing frame 
Lumbar nerves damage (L1 ± 
L5) 
Functional impairments in the hips and legs, might walk with 
assistive devices 
Sacral nerves damage (S1 ± 
S5) 
Temporary loss of some lower-body functions, could walk 
with assistive devices 
Stroke 
Ischemic stroke Highly likely to have permanent weakness of one side of body 
Haemorrhagic stroke Highly likely to have permanent weakness of one side of body 
Spina Bifida 
Myelomeningocele  Highly likely paralysis of lower-body 
Meningocele  Highly likely paralysis of lower-body 
Spina bifida occulta  Sit and walk without any assistance 
 
